At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
ILB-202 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ILB-202 Administered Intravenously As Single Ascending Doses to Healthy Participants
In Brief
A Phase 1 clinical trial evaluating ILB-202 and Placebo for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ILB-202 Administered Intravenously as Single Ascending Doses to Healthy Participants. Male or female subjects aged 18 to 50 years (inclusive) who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartMay 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedMay 6, 2023
Enrollment StartMay 16, 2023
Primary CompletionOct 4, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.2 years ago
Interventions
ILB-202drug
Single i.v. infusion
Placebodrug
Single i.v. infusion